Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Huseini Kagdi"'
Publikováno v:
PLoS Pathogens, Vol 14, Iss 2, p e1006861 (2018)
Adult T-cell leukaemia/lymphoma (ATL) arises from chronic non-malignant human T lymphotropic virus type-1 (HTLV-1) infection which is characterized by high plasma pro-inflammatory cytokines whereas ATL is characterized by high plasma anti-inflammator
Externí odkaz:
https://doaj.org/article/425e015387f94517adaa6c49472595fb
Autor:
Sameer Gandhi, David Foldes, Richard Hinton, George Nesr, Agapi Parcharidou, Rachael Medland, Catherine Garnett, Huseini Kagdi, Siamak Arami, Vaitsa Katsomitrou, Joel James Robert McCay, Hau Wui Sim
Publikováno v:
Leukemia & Lymphoma. 63:227-230
The UK has been severely affected by the COVID-19 pandemic with over 4.4 million cases and over 127,000 deaths to date (www.gov.uk accessed 17 May 2021). Patients with hematological malignancies wh...
Publikováno v:
International Journal of Laboratory Hematology. 44:10-12
Autor:
Graham P. Taylor, Keisuke Kataoka, Johan Van Weyenbergh, Achiléa L. Bittencourt, Soraya Maria Menezes, Kritika Subramanian, Lourdes Farre, Seishi Ogawa, Huseini Kagdi, Ricardo Khouri, Tim Dierckx
Publikováno v:
International Journal of Cancer
Retinoic acid‐related drugs have shown promising pre‐clinical activity in Adult T‐cell Leukemia/Lymphoma, but RORC signaling has not been explored. Therefore, we investigated transcriptome‐wide interactions of the RORC pathway in HTLV‐1 and
Autor:
Nishanthan Rajakumaraswamy, Huseini Kagdi, Gavin Preston, Adam P Cursley, Guan Xing, Christopher Fegan, Toby A. Eyre, Toby Nicholson, Lin Gu, Amin Islam, Heribert Ramroth, Harry W Smith
Publikováno v:
British journal of haematology. 194(1)
Idelalisib (IDL) is an oral first-in-class phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor approved for chronic lymphocytic leukaemia (CLL) alongside rituximab (R) since 2014. However, little data exist on routine practice. The RETRO-idel was
Autor:
Marife Colis, Catherine Garnett, Siamak Arami, George Nesr, Rincy Koshy, Richard Hinton, Kamala Gurung, Huseini Kagdi, David Foldes, James Phillips, Vaitsa Katsomitrou, Zahbia Saleem, Elvis Aduwa, Ravi Bimolah, Christopher Bailey, Tracy Hui
Publikováno v:
Leukemia & Lymphoma
Infection with SARS-CoV-2 is a significant and highly topical worldwide health and social crisis. To date over 25 million cases of COVID-19 infection have been reported globally with greater than 9...
Publikováno v:
British Journal of Haematology
Publikováno v:
PLoS Pathogens, Vol 14, Iss 2, p e1006861 (2018)
PLoS Pathogens
PLoS Pathogens
Adult T-cell leukaemia/lymphoma (ATL) arises from chronic non-malignant human T lymphotropic virus type-1 (HTLV-1) infection which is characterized by high plasma pro-inflammatory cytokines whereas ATL is characterized by high plasma anti-inflammator
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24ad37cc28b12961ed8ff604e0d74024
http://hdl.handle.net/10044/1/57716
http://hdl.handle.net/10044/1/57716
Autor:
Nishan Rajakumaraswamy, Adam P Cursley, Toby A. Eyre, Christopher Fegan, Gavin Preston, Toby Nicholson, Harry W Smith, Amin Islam, Heribert Ramroth, Huseini Kagdi
Publikováno v:
Blood. 134:1762-1762
Background: B-cell receptor signalling pathway plays a key role in CLL pathogenesis. Overexpression of phosphatidylinositol 3-kinase delta isoform (PI3Kδ) is a characteristic of malignant lymphoid cells {Zhang 2014}. Idelalisib is an oral, selective
Autor:
Huseini Kagdi, Graham Phillip Taylor
Publikováno v:
Blood. 132:2843-2843
Aggressive Adult T-cell leukemia/lymphoma (ATL), a human T lymphotropic virus type 1 (HTLV-1) -associated disease, has a poor prognosis. There is an urgent need for effective prevention and treatment. A large number of genomic aberrations including h